Incorporated in late 2021, AtomVie Global Radiopharma has announced the execution of a Lease Agreement with Panattoni Development Company in Ontario, Canada, for its new state-of-the-art radiotherapeutics facility.
AtomVie's new facility will be dedicated to high-volume clinical and commercial GMP manufacturing and worldwide distribution of radiotherapeutics, an innovative, high-growth class of drugs for the treatment of cancer patients.
Currently located on the McMaster University campus, AtomVie successfully operates a global Contract Development and Manufacturing Organisation (CDMO) facility that is home to more than 10 international radiopharmaceutical GMP manufacturing programmes.
We are thrilled to continue being part of the Hamilton radiopharmaceutical ecosystem and by partnering with Panattoni, we were able to choose our new facility's home to meet clinical and commercial supply needs for radiotherapeutics
- Bruno Paquin, CEO of AtomVie Global Radiopharma
The new 64,000 sqft facility in Hamilton is expected to be commissioned in 2024, and will increase production capacity more than 10 times. This will allow the expansion of its clinical and commercial operations to meet the needs of the rapidly expanding radiopharmaceutical market.
Hallmarks of the new facility include cleanrooms and laboratories to sustain over 18 production lines and space for dedicated, high-volume commercial manufacturing.
The facility is strategically located in proximity of the Toronto Pearson International Airport, the John C. Munro Hamilton International Airport and the US border. AtomVie is well positioned to solidify and grow its presence as a global leader in radiopharmaceutical GMP manufacturing, serving patients locally and worldwide.
"AtomVie celebrates yet another milestone by beginning a buildout that will increase our capacity more than ten-fold" said Bruno Paquin, CEO of AtomVie Global Radiopharma. "We are thrilled to continue being part of the Hamilton radiopharmaceutical ecosystem and by partnering with Panattoni, we were able to choose our new facility's home to meet clinical and commercial supply needs for radiotherapeutics, resulting in patients receiving much-needed therapies."
Kevin McNeill, Partner at Avego and AtomVie's Chair of the Board of Directors added: "AtomVie's new facility will provide much-needed capacity for the high-growth global radiopharmaceutical market. We are pleased to be able to meet the expanding needs of our clients and patients."
